Magnetic resonance in the era of molecular imaging of cancer

Magnetic Resonance Imaging

Volumn 29, Issue 5, 2011, Pages 587-600

  Gore, John C ^a   Manning, H Charles ^a   Quarles, C Chad ^a   Waddell, Kevin W ^a   Yankeelov, Thomas E ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Biomarker; Cancer; Molecular imaging

Indexed keywords

AXITINIB; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUORODEOXYGLUCOSE; FLUOROURACIL; GADOLINIUM PENTETATE; TRASTUZUMAB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

BLOOD FLOW; BRAIN CANCER; BREAST CANCER; CANCER DIAGNOSIS; CELL DENSITY; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DRUG TARGETING; HUMAN; HYPERPOLARIZATION; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MALIGNANT NEOPLASTIC DISEASE; MAMMOGRAPHY; METASTASIS; MOLECULAR IMAGING; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL RESOLUTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL DETECTION; SIGNAL NOISE RATIO; SPECTRAL SENSITIVITY; TREATMENT RESPONSE; TUMOR VASCULARIZATION;

ANIMALS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CONTRAST MEDIA; DIAGNOSTIC IMAGING; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEDICAL ONCOLOGY; MEMBRANE PROTEINS; MOLECULAR IMAGING; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79956161755     PISSN: 0730725X     EISSN: 18735894     Source Type: Journal    
DOI: 10.1016/j.mri.2011.02.003     Document Type: Review

References (98)

1. Pruessmann K.P., Weiger M., Scheidegger M.B., Boesiger P. SENSE: sensitivity encoding for fast MRI. Magn Reson Med 1999, 42:952-962.
2. Lustig M., Donoho D., Pauly J.M., Sparse M.R.I. The application of compressed sensing for rapid MR imaging. Magn Reson Med 2007, 58:1182-1195.
3. Robitaille P.M., Abduljalil A.M., Kangarlu A. Ultra high resolution imaging of the human head at 8 tesla: 2K × 2K for Y2K. J Comput Assist Tomogr 2000, 24:2-8.
4. Molecular Imaging Center of Excellence, Society of Nuclear Medicine; available from: http://www.molecularimagingcenter.org.
5. Atkinson A.J., Colburn W.A., DeGruttola V.G., DeMets D.L., Downing G.J., Hoth D.F., et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001, 69:89-95.
6. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
7. Zhong J.H., Gore J.C. Studies of restricted diffusion in heterogeneous media containing variations in susceptibility. Magn Reson Med 1991, 19:276-284.
8. Anderson A.W., Zhong J., Petroff O.A.C., Szafer A., Ransom B.R., Prichard J.W., et al. Effects of osmotically-driven cell volume changes on diffusion weighted imaging of the rat optic nerve. Magn Reson Med 1995, 35:162-167.
9. Sugahara T., Korogi Y., Kochi M., Ikushima I., Shigematu Y., Hirai T., et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 1999, 9:53-60.
10. Lyng H., Haraldseth O., Rofstad E.K. Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med 2000, 43:828-836.
11. Tsuruda J.S., Chew W.M., Moseley M.E., Norman D. Diffusion-weighted MR imaging of extraaxial tumors. Magn Reson Med 1991, 19:316-320.
12. Maeda M., Kawamura Y., Tamagawa Y., Matsuda T., Itoh S., Kimura H., et al. Intravoxel incoherent motion (IVIM) MRI in intracranial, extraaxial tumors and cysts. J Comput Assist Tomogr 1992, 16:514-518.
13. Tien R.D., Felsberg G.J., Friedman H., Brown M., MacFall J. MR imaging of high-grade cerebral gliomas: value of diffusion-weighted echoplanar pulse sequences. AJR Am J Roentgenol 1994, 162:671-677.
14. Brunberg J.A., Chenevert T.L., McKeever P.E., Ross D.A., Junck L.R., Muraszko K.M., et al. In vivo MR determination of water diffusion coefficients and diffusion anisotropy: correlation with structural alteration in gliomas of the cerebral hemispheres. AJNR Am J Neuroradiol 1995, 16:361-371.
15. Eis M., Els T., Hoehn-Berlage M. High resolution quantitative relaxation and diffusion MRI of three different experimental brain tumors in rat. Magn Reson Med 1995, 34:835-844.
16. Zhao M., Pipe J.G., Bonnett J., Evelhoch J.L. Early detection of treatment response by diffusion-weighted 1H-NMR spectroscopy in a murine tumour in vivo. Br J Cancer 1996, 73:61-64.
17. Chenevert T.L., McKeever P.E., Ross B.D. Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res 1997, 3:1457-1466.
18. Chenevert T.L., Stegman L.D., Taylor J.M.G., Robertson P.L., Greenberg H.S., Rehemtulla A., et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000, 92:2029-2036.
19. Hakumaki J.M., Poptani H., Puumalainen A.M., Loimas S., Paljarvi L.A., Yla-Herttuala S., et al. Quantitative H-1 nuclear magnetic resonance diffusion spectroscopy of BT4C rat glioma during thymidine kinase-mediated gene therapy in vivo: identification of apoptotic response. Cancer Res 1998, 58:3791-3799.
20. Poptani H., Puumalainen A.M., Grohn O.H., Loimas S., Kainulainen R., Yla-Herttuala S., Kauppinen R.A. Monitoring thymidine kinase and ganciclovir-induced changes in rat malignant glioma in vivo by nuclear magnetic resonance imaging. Cancer Gene Ther 1998, 5:101-109.
21. Galons J.P., Altbach M.I., Paine-Murrieta G.D., Taylor C.W., Gillies R.J. Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia 1999, 1:113-117.
22. Stegman L.D., Rehemtulla A., Hamstra D.A., Rice D.J., Jonas S.J., Stout K.L., et al. Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy. Gene Ther 2000, 7:1005-1010.
23. Guo A.C., Cummings T.J., Dash R.C., Provenzale J.M. Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology 2002, 224:177-183.
24. Kauppinen R.A. Monitoring cytotoxic tumour treatment response by diffusion magnetic resonance imaging and proton spectroscopy. NMR Biomed 2002, 15:6-17.
25. Brauer M. In vivo monitoring of apoptosis. Prog Neuro-Psychopharmacol Biol Psychiatry 2003, 27:323-331.
26. Dzik-Jurasz A., Domenig C., George M., Wolber J., Padhani A., Brown G., et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 2002, 360(9329):307-308.
27. Koh D.M., Scurr E., Collins D., Kanber B., Norman A., Leach M.O., et al. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR Am J Roentgenol. 2007, 188:1001-1008.
28. Cui Y., Zhang X.P., Sun Y.S., Tang L., Shen L. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 2008, 248:894-900.
29. Moffat B.A., Chenevert T.L., Lawrence T.S., Meyer C.R., Johnson T.D., Dong Q., et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A 2005, 102:5524-5529.
30. Hall D.E., Moffat B.A., Stojanovska J., Johnson T.D., Li Z., Hamstra D.A., et al. Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin Cancer Res 2004, 10(23):7852-7859.
31. Lee K.C., Sud S., Meyer C.R., Moffat B.A., Chenevert T.L., Rehemtulla A., et al. An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. Cancer Res 2007, 67(8):3524-3528.
32. Yankeelov T.E., Lepage M., Chakravarthy A., Broome E.E., Niermann K.J., Kelley M.C., et al. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging 2007, 25:1-13.
33. Morse D.L., Galons J.P., Payne C.M., Jennings D.L., Day S., Xia G., et al. MRI-measured water mobility increases in response to chemotherapy via multiple cell-death mechanisms. NMR Biomed 2007, 20(6):602-614.
34. Kim H., Morgan D.E., Zeng H., Grizzle W.E., Warram J.M., Stockard C.R., et al. Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody. Radiology 2008, 248(3):844-851.
35. Seierstad T., Røe K., Olsen D.R. Noninvasive monitoring of radiation-induced treatment response using proton magnetic resonance spectroscopy and diffusion-weighted magnetic resonance imaging in a colorectal tumor model. Radiother Oncol 2007, 85(2):187-194.
36. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1:27-31.
37. Yankeelov T.E., Gore J.C. Dynamic contrast enhanced magnetic resonance imaging in oncology: theory, data acquisition, analysis, and examples. Curr Med Imaging Rev 2007, 3:91-107.
38. Li K.L., Wilmes L.J., Henry R.G., Pallavicini M.G., Park J.W., Hu-Lowe D.D., et al. Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI. J Magn Reson Imaging 2005, 22:511-519.
39. Ellingsen C., Egeland T.A., Gulliksrud K., Gaustad J.V., Mathiesen B., Rofstad E.K. Assessment of hypoxia in human cervical carcinoma xenografts by dynamic contrast-enhanced magnetic resonance imaging. Int J Radiat Oncol Biol Phys 2009, 73:838-845.
40. Dafni H., Kim S.J., Bankson J.A., Sankaranarayanapillai M., Ronen S.M. Macromolecular dynamic contrast-enhanced (DCE)-MRI detects reduced vascular permeability in a prostate cancer bone metastasis model following anti-platelet-derived growth factor receptor (PDGFR) therapy, indicating a drop in vascular endothelial growth factor receptor (VEGFR) activation. Magn Reson Med 2008, 60:822-833.
41. Moasser M.M., Wilmes L.J., Wong C.H., Aliu S., Li K.L., Wang D., et al. Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Magn Reson Imaging 2007, 26:1618-1625.
42. Muruganandham M., Lupu M., Dyke J.P., Matei C., Linn M., Packman K., et al. Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T. Mol Cancer Ther 2006, 5:1950-1957.
43. Marzola P., Degrassi A., Calderan L., Farace P., Nicolato E., Crescimanno C., et al. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin Cancer Res 2005, 11:5827-5832.
44. Ah-See M.L.W., Makris A., Taylor N.J., Harrison M., Richman P.I., Burcombe R.J., et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2008, 14:6580-6589.
45. Hahn O.M., Yang C., Medved M., Karczmar G., Kistner E., Karrison T., et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 2008, 26:4572-4578.
46. Li K.L., Henry R.G., Wilmes L.J., Gibbs J., Zhu X., Lu Y., et al. Kinetic assessment of breast tumors using high spatial resolution signal enhancement ratio (SER) imaging. Magn Reson Med 2007, 58:572-581.
47. Oberholzer K., Pohlmann A., Schreiber W., Mildenberger P., Kunz P., Schmidberger H., et al. Assessment of tumor microcirculation with dynamic contrast-enhanced MRI in patients with esophageal cancer: initial experience. J Magn Reson Imaging 2008, 27:1296-1301.
48. Radjenovic A., Dall B.J., Ridgway J.P., Smith M.A. Measurement of pharmacokinetic parameters in histologically graded invasive breast tumours using dynamic contrast-enhanced MRI. Br J Radiol 2008, 81:120-128.
49. Haider M.A., Sitartchouk I., Roberts T.P., Fyles A., Hashmi A.T., Milosevic M. Correlations between dynamic contrast-enhanced magnetic resonance imaging-derived measures of tumor microvasculature and interstitial fluid pressure in patients with cervical cancer. J Magn Reson Imaging 2007, 25:153-159.
50. Kennan R.P., Zhong J., Gore J.C. Intravascular susceptibility contrast mechanisms in tissues. Magn Reson Med 1994, 31:9-21.
51. Aronen H.J., Gazit I.E., Louis D.N., Buchbinder B.R., Pardo F.S., Weisskoff R.M., et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994, 191(1):41-51.
52. Donahue K.M., Krouwer H.G., Rand S.D., Pathak A.P., Marszalkowski C.S., Censky S.C., et al. Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients. Magn Reson Med 2000, 43(6):845-853.
53. Schmainda K.M., Rand S.D., Joseph A.M., Lund R., Ward B.D., Pathak A.P., et al. Characterization of a first-pass gradient-echo spin-echo method to predict brain tumor grade and angiogenesis. AJNR Am J Neuroradiol 2004, 25(9):1524-1532.
54. Hakyemez B., Erdogan C., Ercan I., Ergin N., Uysal S., Atahan S. High-grade and low-grade gliomas: differentiation by using perfusion MR imaging. Clin Radiol 2005, 60(4):493-502.
55. Fuss M., Wenz F., Essig M., Muenter M., Debus J., Herman T.S., et al. Tumor angiogenesis of low-grade astrocytomas measured by dynamic susceptibility contrast-enhanced MRI (DSC-MRI) is predictive of local tumor control after radiation therapy. Int J Radiat Oncol Biol Physics 2001, 51(2):478-482.
56. Weber M.A., Thilmann C., Lichy M.P., Gunther M., Delorme S., Zuna I., et al. Assessment of irradiated brain metastases by means of arterial spin-labeling and dynamic susceptibility-weighted contrast-enhanced perfusion MRI: initial results. Invest Radiol 2004, 39(5):277-287.
57. Lee M.C., Cha S., Chang S.M., Nelson S.J. Dynamic susceptibility contrast perfusion imaging of radiation effects in normal-appearing brain tissue: changes in the first-pass and recirculation phases. J Magn Reson Imaging 2005, 21(6):683-693.
58. Delile J., Slanetz P., Yeh E., Kopans D., Garrido L. Breast cancer: regional blood flow and volume with magnetic susceptibility-based MR imaging. Radiology 2002, 223:558-565.
59. Ludemann L., Prochnow D., Rohlfing T., Franiel T., Warmuth C., Taupitz M., et al. Simultaneous quantification of perfusion and permeability in the prostate using dynamic contrast-enhanced magnetic resonance imaging with an inversion-prepared dual-contrast sequence. Ann Biomed Eng 2009, 37(4):749-762.
60. Tropes I., Grimault S., Vaeth A., Grillon E., Julien C., Payen J.F., et al. Vessel Size Imaging. Magn Reson Med 2001, 45:397-408.
61. Quarles C.C., Gochberg D.F., Gore J.C., Yankeelov T.E. A theoretical framework to model DSC-MRI data acquired in the presence of contrast agent extravasation. Phys Med Biol 2009, 54(19):5749-5766.
62. Kreis R. Quantitative localized 1H MR spectroscopy for clinical use. Prog Nucl Magn Reson Spectroscopy 1997, 31:155-195.
63. Osorio J.A., Ozturk-Isik E., Xu D., Cha S., Chang S., Berger M.S., et al. 3D 1H MRSI of brain tumors at 3.0 Tesla using an eight-channel phased-array head coil. J Magn Reson Imaging 2007, 26:23-30.
64. Sherry A.D., Woods M. Chemical exchange saturation transfer contrast agents for magnetic resonance imaging. Annu Rev Biomed Eng 2008, 10:391-411.
65. Bellin M.F., Vasile M., Morel-Precetti S. Currently used non-specific extracellular MR contrast media. Eur Radiol 2003, 13:2688-2698.
66. Mohs A.M., Lu Z.R. Gadolinium(III)-based blood-pool contrast agents for magnetic resonance imaging: status and clinical potential. Expert Opin Drug Deliv 2007, 4:149-164.
67. Artemov D. Molecular magnetic resonance imaging with targeted contrast agents. J Cell Biochem 2003, 90:518-524.
68. Krishnan A.S., Neves A.A., de Backer M.M., Hu D.E., Davletov B., Kettunen M.I., et al. Detection of cell death in tumors by using MR imaging and a gadolinium-based targeted contrast agent. Radiology 2008, 246(3):854-862.
69. Lepage M., Dow W.C., Melchior M., You Y., Fingleton B., Quarles C.C., et al. Noninvasive detection of matrix metalloproteinase activity in vivo using a novel magnetic resonance imaging contrast agent with a solubility switch. Mol Imaging 2007, 6:393-403.
70. Yoo B., Pagel M.D. An overview of responsive MRI contrast agents for molecular imaging. Front Biosci 2008, 13:1733-1752.
71. Rogers W.J., Meyer C.H., Kramer C.M. Technology insight: in vivo cell tracking by use of MRI. Nat Clin Pract Cardiovasc Med 2006, 3:554-562.
72. Bulte J.W., Duncan I.D., Frank J.A. In vivo magnetic resonance tracking of magnetically labeled cells after transplantation. J Cereb Blood Flow Metab 2002, 22:899-907.
73. Gore J.C., Joers J.M., Kennan R.P. Contrast agents and relaxation effects. Magnetic resonance imaging of the brain and spine 2002, 79-99. Williams and Wilkins, Lippincott, Chapter 4. 3rd ed. S. Atlas (Ed.).
74. Majumdar S., Zoghbi S.S., Pope C.F., Gore J.C.A. Quantitative study of relaxation rate enhancement produced by iron-oxide particles in polyacrylamide gels and tissue. Magn Reson Med 1989, 9:185-202.
75. Zhang S., Merritt M., Woessner D.E., Lenkinski R.E., Sherry A.D. PARACEST agents: modulating MRI contrast via water proton exchange. Acc Chem Res 2003, 36:783-790.
76. Woods M., Woessner D.E., Sherry A.D. Paramagnetic lanthanide complexes as PARACEST agents for medical imaging. Chem Soc Rev 2006, 5(6):500-511.
77. Ren J., Trokowski R., Zhang S., Malloy C.R., Sherry A.D. Imaging the tissue distribution of glucose in livers using a PARACEST sensor. Magn Reson Med 2008, 60(5):1047-1055.
78. Louie A.Y., Hüber M.M., Ahrens E.T., Rothbächer U., Moats R., Jacobs R.E., et al. In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol 2000, 18(3):321-325.
79. Wu Y., Soesbe T.C., Kiefer G.E., Zhao P., Sherry A.D. A responsive europium(III) chelate that provides a direct readout of pH by MRI. J Am Chem Soc 2010, 132(40):14002-14003.
80. Ren J., Trokowski R., Zhang S., Malloy C.R., Sherry A.D. Imaging the tissue distribution of glucose in livers using a PARACEST sensor. Magn Reson Med 2008, 60(5):1047-1055.
81. Dixon W.T. Simple proton spectroscopic imaging. Radiology 1984, 153(1):189-194.
82. Vigneron D.B., Nelson S.J., Murphy-Boesch J., Kelley D.A., Kessler H.B., Brown T.R., et al. Chemical shift imaging of human brain: axial, sagittal, and coronal P-31 metabolite images. Radiology 1990, 177(3):643-649.
83. Behar K.L., Petroff O.A., Prichard J.W., Alger J.R., Shulman R.G. Detection of metabolites in rabbit brain by 13C NMR spectroscopy following administration of [1-13C]glucose. Magn Reson Med 1986, 3(6):911-920.
84. Gruetter R., Novotny E.J., Boulware S.D., Mason G.F., Rothman D.L., Shulman G.I., et al. Localized 13C NMR spectroscopy in the human brain of amino acid labeling from D-[1-13C]glucose. J Neurochem 1994, 63(4):1377-1385.
85. Zhou J., Lal B., Wilson D.A., Laterra J., van Zijl P.C. Amide proton transfer (APT) contrast for imaging of brain tumors. Magn Reson Med 2003, 50(6):1120-1126.
86. van Zijl P.C., Jones C.K., Ren J., Malloy C.R., Sherry A.D. MRI detection of glycogen in vivo by using chemical exchange saturation transfer imaging (glycoCEST). Proc Natl Acad Sci U S A 2007, 104(11):4359-4364.
87. Middleton H., Black R.D., Saam B., Cates G.D., Cofer G.P., Guenther R., et al. MR imaging with hyperpolarized 3He gas. Magn Reson Med 1995, 33(2):271-275.
88. Mugler J.P., Driehuys B., Brookeman J.R., Cates G.D., Berr S.S., Bryant R.G., et al. MR imaging and spectroscopy using hyperpolarized 129Xe gas: preliminary human results. Magn Reson Med 1997, 37(6):809-815.
89. Golman K., Olsson L.E., Axelsson O., Månsson S., Karlsson M., Petersson J.S. Molecular imaging using hyperpolarized 13C. Br J Radiol 2003, 76(Spec No 2):S118-S127.
90. Cudalbu C., Comment A., Kurdzesau F., van Heeswijk R.B., Uffmann K., Jannin S., et al. Feasibility of in vivo 15N MRS detection of hyperpolarized 15N labeled choline in rats. Phys Chem Chem Phys 2010, 12(22):5818-5823.
91. Witney T.H., Kettunen M.I., Day S.E., Hu D.E., Neves A.A., Gallagher F.A., et al. A comparison between radiolabeled fluorodeoxyglucose uptake and hyperpolarized (13)C-labeled pyruvate utilization as methods for detecting tumor response to treatment. Neoplasia 2009, 11(6):574-582.
92. Golman K., Zandt R.I., Lerche M., Pehrson R., Ardenkjaer-Larsen J.H. Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor diagnosis. Cancer Res 2006, 66(22):10855-10860.
93. Albers M.J., Bok R., Chen A.P., Cunningham C.H., Zierhut M.L., Zhang V.Y., et al. Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res 2008, 68(20):8607-8615.
94. Day S.E., Kettunen M.I., Gallagher F.A., Hu D.E., Lerche M., Wolber J., et al. Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy. Nat Med 2007, 13(11):1382-1387. Erratum in: Nat Med. 2007 Dec;13(12):1521.
95. Gallagher F.A., Kettunen M.I., Day S.E., Hu D.E., Ardenkjaer-Larsen J.H., Zandt R., et al. Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate. Nature 2008, 453(7197):940-943.
96. Gallagher F.A., Kettunen M.I., Hu D.E., Jensen P.R., Zandt R.I., Karlsson M., et al. Production of hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors. Proc Natl Acad Sci U S A 2009, 106(47):19801-19806.
97. Gabellieri C., Reynolds S., Lavie A., Payne G.S., Leach M.O., Eykyn T.R. Therapeutic target metabolism observed using hyperpolarized 15N choline. J Am Chem Soc 2008, 130(14):4598-4599.
98. Gore J.C., Yankeelov T.E., Peterson T.E., Avison M.J. Molecular imaging without radiopharmaceuticals?. J Nucl Med 2009, 50(6):999-1007.